Atea Pharmaceuticals, Inc.

Overview

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antiviral therapies to address significant unmet medical needs. The company's lead product candidate is AT-527, an orally administered, direct-acting antiviral in clinical trials for the treatment of COVID-19.

Therapeutic areas

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Atea Pharmaceuticals, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.